Cellular immune response to cryptic epitopes during therapeutic gene transfer.
about
Direct detection of alternative open reading frames translation products in human significantly expands the proteomeDevelopments in the treatment of hemophilia B: focus on emerging gene therapyGene therapy on the moveAnimal models of hemophiliaCardiac-targeted delivery of regulatory RNA molecules and genes for the treatment of heart failureAAV's anatomy: roadmap for optimizing vectors for translational successThe pleiotropic effects of natural AAV infections on liver-directed gene transfer in macaquesAdjuvant-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release.Viral vectors for neurotrophic factor delivery: a gene therapy approach for neurodegenerative diseases of the CNSAdeno-associated virus (AAV) vectors in gene therapy: immune challenges and strategies to circumvent them.Adeno-associated virus vectors serotype 2 induce prolonged proliferation of capsid-specific CD8+ T cells in mice.Non-conventional sources of peptides presented by MHC class I.Systemic elimination of de novo capsid protein synthesis from replication-competent AAV contamination in the liverCodon optimization of the human papillomavirus E7 oncogene induces a CD8+ T cell response to a cryptic epitope not harbored by wild-type E7Adenovirus-associated virus vector-mediated gene transfer in hemophilia BPreclinical evaluation of a clinical candidate AAV8 vector for ornithine transcarbamylase (OTC) deficiency reveals functional enzyme from each persisting vector genome.Vector Design for Improved DNA Vaccine Efficacy, Safety and Production.Integration frequency and intermolecular recombination of rAAV vectors in non-human primate skeletal muscle and liver.Enhanced Recognition of HIV-1 Cryptic Epitopes Restricted by HLA Class I Alleles Associated With a Favorable Clinical Outcome.Death of a dogma: eukaryotic mRNAs can code for more than one protein.Adeno-associated virus capsid antigen presentation is dependent on endosomal escape.Adeno-associated viral vectors for the treatment of hemophilia.Kinetics of adeno-associated virus serotype 2 (AAV2) and AAV8 capsid antigen presentation in vivo are identical.Immune responses to AAV vectors: overcoming barriers to successful gene therapyNowhere to hide: unconventional translation yields cryptic peptides for immune surveillanceViral infection causes a shift in the self peptide repertoire presented by human MHC class I molecules.A translationally optimized AAV-UGT1A1 vector drives safe and long-lasting correction of Crigler-Najjar syndrome.Oversized AAV transductifon is mediated via a DNA-PKcs-independent, Rad51C-dependent repair pathway.Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodiesGene therapy for haemophilia: a long and winding road.Recent Developments in Gene Therapy for Homozygous Familial Hypercholesterolemia.Small proteins encoded by unannotated ORFs are rising stars of the proteome, confirming shortcomings in genome annotations and current vision of an mRNA.Liver-Directed Adeno-Associated Viral Gene Therapy for Hemophilia.Presentation of Cryptic Peptides by MHC Class I Is Enhanced by Inflammatory Stimuli.AAV vector-meditated expression of HLA-G reduces injury-induced corneal vascularization, immune cell infiltration, and fibrosis.Inhibition of antigen presentation during AAV gene therapy using virus peptides.
P2860
Q21132658-115DE26F-5AD5-4628-9709-E9BB9BCB5DDEQ26823376-77DC67E1-0876-4A8A-BCDC-E2D462E3B525Q27007012-4470D29B-CEAA-4C88-83C4-E2ABB8FE3278Q27012571-3CA56C78-6855-4CD8-BDC1-9FA38FB3D1CFQ27691424-D6842E13-B5E3-4B18-B855-4F8FA024420FQ33659389-0FFCFE49-A89F-434E-B63A-59F86D0F5183Q33730459-041D6C20-A86F-4760-93D8-E3440989F7CCQ33760871-016DA298-D1D1-4DB2-AD56-5A3F34DF1270Q33894621-749CAB04-9786-4C4B-9A90-81A83923C253Q34370111-2803F312-C14A-4B6B-B1EA-B1883CFE97E2Q34621723-062A669B-3E45-4E06-9097-ABB1A9E892B8Q34768462-A9FAE269-4A0F-4B85-B1D5-E97310C34431Q34843835-325DDC64-B8B8-47EF-9BA5-840D55AF8C56Q35208290-3571A793-BA71-4053-8ED2-A425EF7DCE03Q35691659-65CF58BF-7313-4500-A439-C2F0E3133FD4Q35726773-5756E8DE-5D0E-4ECB-A0D6-A84519F2C4F5Q35826665-6ADC02DF-5657-4428-AAFF-AAB529F2E285Q36014088-435AA873-80FC-4E6A-B5F5-A627A70F86F7Q36015624-E9312E73-6D3B-4256-A61B-6FE882C43F6CQ36443272-FC672D2E-702F-43FD-8E79-4C537EB879F2Q36638203-409E05E5-19EB-4444-8A8D-5B58CAFF5421Q36713767-ADFD7462-DB06-4CE5-8977-4D075A273A65Q36848699-C69515A7-28CD-4A76-9700-50D0A39215ECQ36983740-AF1F2F0D-D281-4BA5-83CC-6B54F6775FD7Q37028320-338CAB85-E746-4D54-92AC-78AEA7B30D4EQ37035972-9130B7C4-D78C-4362-8534-0311BE541791Q37313599-5485B69F-D747-4D66-9D21-ADC6C95F7316Q37393799-8DAF104B-868A-44BE-A7BA-A7B1BD0B3B5CQ37621530-A96DAF4B-4AA1-4F7E-B885-FE6ACFAF8775Q37903924-34E62AB1-3C7A-4A2A-B696-4FEFADE7939EQ38776037-A03160E9-F3A0-4AFB-A17C-D3ECA81D0F89Q39382046-56363DB9-92F7-4418-8327-536D403E3ED1Q39553052-1C243693-BAFF-4625-8314-FAF66AC3B2B0Q40534425-C5A37020-2ACE-41B6-BC0E-68FAF1F2604FQ47108441-E98B241E-81E2-46E2-BC5C-C04997695E0EQ47260510-73E9B43F-2E37-40DA-8880-DEECFCEB78A8
P2860
Cellular immune response to cryptic epitopes during therapeutic gene transfer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cellular immune response to cryptic epitopes during therapeutic gene transfer.
@en
Cellular immune response to cryptic epitopes during therapeutic gene transfer.
@nl
type
label
Cellular immune response to cryptic epitopes during therapeutic gene transfer.
@en
Cellular immune response to cryptic epitopes during therapeutic gene transfer.
@nl
prefLabel
Cellular immune response to cryptic epitopes during therapeutic gene transfer.
@en
Cellular immune response to cryptic epitopes during therapeutic gene transfer.
@nl
P2093
P2860
P356
P1476
Cellular immune response to cryptic epitopes during therapeutic gene transfer.
@en
P2093
Aravind Asokan
Chengwen Li
David Seiber
Jeff Alexander
Jeff Frelinger
John Sidney
Junjiang Sun
Kevin Goudy
Matt Hirsch
Paul Monahan
P2860
P304
10770-10774
P356
10.1073/PNAS.0902269106
P407
P577
2009-06-16T00:00:00Z